Equities

PeptiDream Inc

PeptiDream Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)2,015.00
  • Today's Change17.00 / 0.85%
  • Shares traded199.90k
  • 1 Year change-2.80%
  • Beta0.9759
Data delayed at least 20 minutes, as of Feb 06 2023 00:22 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).

  • Revenue in JPY (TTM)12.81bn
  • Net income in JPY56.80m
  • Incorporated2006
  • Employees141.00
  • Location
    PeptiDream Inc3-25-23, Tono-machi, Kawasaki-kuKAWASAKI-SHI 210-0821JapanJPN
  • Phone+81 442701300
  • Websitehttps://www.peptidream.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Mochida Pharmaceutical Co Ltd109.37bn9.58bn135.74bn1.54k13.370.975511.101.24252.77252.772,899.753,464.880.6782.243.5870,835,500.005.945.227.126.4053.9951.578.757.763.62--0.0040.566.982.5123.084.3921.993.04
KAKEN PHARMACEUTICAL CO., LTD.73.90bn8.45bn166.76bn1.16k16.140.970823.352.26224.91224.911,962.433,739.380.44062.002.8463,487,110.005.0410.155.7712.0654.2956.0911.4418.284.98--0.026637.001.41-5.61-28.77-15.396.710.00
Sawai Group Holdings Co Ltd192.93bn-31.03bn170.35bn2.97k--0.8422--0.883-709.06-709.064,400.234,618.620.49431.482.8865,002,360.00-11.391.25-15.971.7031.7638.97-23.052.461.24-155.680.258576.823.527.92-329.08--4.380.00
Sosei Group Corporation22.76bn-383.00m197.11bn198.00--3.54211.048.66-4.70-4.70278.03679.920.2473--19.92114,964,600.00-0.416---0.4321--95.45---1.68----2.570.3475--100.32---31.24------
JCR Pharmaceuticals Co Ltd37.51bn5.15bn207.24bn816.0038.733.8351.085.5341.2641.26301.20417.040.40520.64192.6445,965,690.005.5911.479.3316.2771.9273.5813.8020.620.8526--0.257122.4669.7923.08110.4950.7548.8629.46
TAKARA BIO INC.68.74bn18.38bn207.84bn1.67k11.311.959.113.02152.62152.62570.82886.080.61151.214.5941,257,500.0016.399.9418.7911.1669.4665.3726.8118.174.3137.630.0021.0346.9018.17107.9171.1452.5752.51
Tsumura & Co138.24bn19.32bn208.09bn3.92k10.730.80346.771.51252.68252.681,807.883,374.390.37390.73932.3935,256,310.005.535.196.656.2849.6555.7814.7812.783.89--0.221831.4511.282.4222.858.574.990.00
Peptidream Inc12.81bn56.80m259.76bn141.004,629.7210.60162.3720.280.43160.431698.66188.500.32373.973.15--0.1435--0.1626--50.04--0.4434--1.92--0.4629---19.79---18.93------
Hisamitsu Pharmaceutical Co Inc125.41bn12.96bn333.42bn2.78k24.111.1518.722.66162.40162.401,571.353,393.170.39142.883.5845,047,060.004.145.154.815.8356.6761.1610.5711.523.86--0.004544.974.96-3.814.41-13.895.560.6061
Sumitomo Pharma Co Ltd588.23bn-8.45bn342.59bn6.99k--0.538622.780.5824-21.27-21.271,480.561,598.700.4411.943.8684,188,920.00-2.044.10-2.785.9769.5673.85-4.638.671.58--0.263521.778.546.520.345112.490.0529.24
Santen Pharmaceutical Co Ltd266.41bn-9.14bn383.17bn4.32k--1.2344.101.44-26.56-26.56675.20799.460.62912.843.0661,741,140.00-2.146.25-2.597.5657.7060.55-3.4110.302.36--0.168843.856.675.99192.384.6030.424.24
Data as of Feb 06 2023. Currency figures normalised to PeptiDream Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

28.95%Per cent of shares held by top holders
HolderShares% Held
Taiyo Pacific Partners LPas of 29 Aug 20229.36m7.20%
JOHCM (Singapore) Pte Ltd.as of 24 Aug 20215.75m4.42%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 15 Dec 20225.41m4.16%
Nomura Asset Management Co., Ltd.as of 30 Dec 20223.13m2.41%
Baillie Gifford & Co.as of 31 Dec 20223.07m2.36%
Invesco Advisers, Inc.as of 31 Dec 20223.05m2.35%
The Vanguard Group, Inc.as of 05 Jan 20232.28m1.75%
Alma Capital Investment Management SA (UK)as of 30 Jun 20221.95m1.50%
BlackRock Fund Advisorsas of 30 Nov 20211.82m1.40%
Nikko Asset Management Co., Ltd.as of 15 Dec 20221.81m1.40%
More ▼
Data from 30 Sep 2019 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.